Dashboard
Manage Tickers

GILDGILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 73.64 $ -1.93 (-2.55 %)    

Friday, 09-Aug-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 73.66
$ 73.63 x 400
-- x --
-- - --
$ 61.32 - $ 85.92
9,545,056
na
92.15B
$ 0.31
$ 87.43
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-23-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-04-2023 06-30-2023 10-Q
6 05-03-2023 03-31-2023 10-Q
7 02-22-2023 12-31-2022 10-K
8 11-02-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 02-23-2022 12-31-2021 10-K
12 11-03-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-26-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-06-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 02-27-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 02-24-2016 12-31-2015 10-K
36 11-04-2015 09-30-2015 10-Q
37 08-05-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 02-25-2015 12-31-2014 10-K
40 11-05-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rbc-capital-maintains-sector-perform-on-gilead-sciences-raises-price-target-to-72
RBC Capital Maintains Sector Perform on Gi...
08/09/2024 19:25:24

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target...

analysts-cite-improved-investor-sentiment-for-gilead-but-warn-of-limited-growth-at-current-stock-levels
Analysts Cite Improved Investor Sentiment ...
08/09/2024 17:48:23

Gilead Sciences' Q2 2024 revenue rose to $6.95B, beating expectations, driven by strong performance in HIV, Liver Disease, ...

wall-street-momentum-stalls-after-thursdays-rally-palantir-jumps-to-3-year-highs-bonds-rally-whats-driving-markets-friday
Wall Street Momentum Stalls After Thursday...
08/09/2024 17:13:36

After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s ...

cantor-fitzgerald-reiterates-neutral-on-gilead-sciences-maintains-70-price-target
Cantor Fitzgerald Reiterates Neutral on Gi...
08/09/2024 15:36:11

Cantor Fitzgerald analyst Olivia Brayer reiterates Gilead Sciences (NASDAQ:GILD) with a Neutral and maintains $70 price target.

bmo-capital-maintains-outperform-on-gilead-sciences-raises-price-target-to-85
BMO Capital Maintains Outperform on Gilead...
08/09/2024 11:53:49

BMO Capital analyst Evan Seigerman maintains Gilead Sciences (NASDAQ:GILD) with a Outperform and raises the price target fro...

gilead-sciences-raises-fy24-adj-eps-forecast-from-345---385-to-360---390-est-375-product-sales-outlook-unchanged
Gilead Sciences Raises FY24 Adj EPS Foreca...
08/08/2024 20:25:48

gilead-sciences-q2-2024-adj-eps-201-beats-160-estimate-sales-6954b-beat-6719b-estimate
Gilead Sciences Q2 2024 Adj. EPS $2.01 Bea...
08/08/2024 20:03:06

Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $2.01 per share which beat the analyst consensus estimate of $1.60...

wall-street-rallies-as-economic-concerns-recede-tech-flexes-its-muscles-semiconductors-soar-whats-driving-markets-thursday
Wall Street Rallies As Economic Concerns R...
08/08/2024 17:19:57

Investor risk sentiment is showing greater conviction on Thursday, with all indices and major stock sectors in the green, after...

wall-street-set-for-uneventful-start-ahead-of-jobless-claim-data-vix-rises-strategist-says-market-may-remain-vulnerable-until
Wall Street Set For Uneventful Start Ahead...
08/08/2024 11:50:25

U.S. stocks are set for a mixed start on Thursday as concerns regarding the economy and incremental yen carry trade unwinding r...

1000-invested-in-gilead-sciences-20-years-ago-would-be-worth-this-much-today
$1000 Invested In Gilead Sciences 20 Years...
08/06/2024 16:00:21

gilead-sciencess-options-frenzy-what-you-need-to-know
Gilead Sciences's Options Frenzy: What You...
07/30/2024 18:01:50

100-invested-in-gilead-sciences-20-years-ago-would-be-worth-this-much-today
$100 Invested In Gilead Sciences 20 Years ...
07/29/2024 19:02:38

wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields
Wall Street's Most Accurate Analysts Say H...
07/29/2024 13:04:02

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
07/26/2024 17:35:23

nasdaq-100-falls-to-7-week-lows-marks-worst-2-day-drop-in-nearly-2-years-as-tech-rout-rages-on
Nasdaq 100 Falls To 7-Week Lows, Marks Wor...
07/25/2024 21:02:53

Nasdaq 100 index falls to its lowest level since June amid volatility. Despite a brief boost from Q2 GDP growth and decreasing ...

this-is-what-whales-are-betting-on-gilead-sciences
This Is What Whales Are Betting On Gilead ...
07/25/2024 15:06:24

gilead-sciences-presents-new-5-year-data-reinforcing-biktarvy-as-long-term-hiv-treatment-investigational-dosing-frequencies-aim-to-expand-options-and-address-unmet-needs-key-findings-presented-at-aids-2024-conference-highlight-innovative-hiv-treatment-portfolio-and-research-pipeline
Gilead Sciences Presents New 5-Year Data R...
07/25/2024 13:16:38

gileads-425k-priced-hiv-drug-could-be-made-at-just-40-annually-campaigners-urge-company-to-slash-price
Gilead's $42.5K Priced HIV Drug Could Be M...
07/24/2024 19:04:07

Gilead Sciences' lenacapavir, marketed as Sunlenca, is under scrutiny for its $42,250 annual price despite research suggest...

gilead-sciences-announced-phase-3-purpose-1-trial-data-showing-zero-infections-and-100-efficacy-and-superiority-of-lenacapavir-to-background-hiv-incidence-for-the-investigational-use-of-hiv-prevention-in-cisgender-women
Gilead Sciences Announced Phase 3 Purpose ...
07/24/2024 08:33:34

pfizer-and-gsks-viiv-healthcares-two-drug-hiv-treatment-matches-gileads-three-drug-combo-in-major-trial
Pfizer And GSK's ViiV Healthcare's Two-Dru...
07/23/2024 18:55:53

ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's b...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION